NASDAQ:VRTX

Vertex to Participate in Upcoming June Investor Conferences

Retrieved on: 
Wednesday, May 22, 2024
Biotechnology, Pharmaceutical, Genetics, Health, Vertex Pharmaceuticals, News, VRTX, Global Research, Conference

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in two upcoming investor conferences.

Key Points: 
  • Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in two upcoming investor conferences.
  • ET.
  • A live webcast of management's remarks will be available through the Vertex website, www.vrtx.com in the "Investors" section under the "News and Events" page.
  • A replay of the conference webcast will be archived on the company's website.

Jennifer Schneider Elected to Vertex Board of Directors

Retrieved on: 
Wednesday, May 15, 2024
Biotechnology, Pharmaceutical, Health, Clinical Trials, Diabetes, Patient, Biology, Hospital, College, Obesity, Stanford University, Internal medicine, Sickle cell disease, Population health, Castlight Health, Vertex Pharmaceuticals, Hypertension, Research, Policy, Woman, Teladoc Health, Cystic fibrosis, Beta thalassemia, VRTX, Holy Cross, History

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Jennifer Schneider, M.D., M.S., has been elected to its Board of Directors as an independent director.

Key Points: 
  • Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Jennifer Schneider, M.D., M.S., has been elected to its Board of Directors as an independent director.
  • Dr. Schneider has more than two decades of experience in the health care industry as a physician, scientist and health care executive.
  • She currently serves on the Board of Directors of Jasper Health and Maven Health.
  • The addition of Dr. Schneider brings Vertex’s board of directors to 11 members, nine of whom are independent and 45% of whom are women.

Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain

Retrieved on: 
Thursday, April 18, 2024
Health, FDA, Neurology, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, VRTX, Pain, Pregabalin, Safety, NDA, Food, New Drug Application, DPN, Sciatica, Fast track (FDA), Week, Patient, Medicine, Neuropathic pain, LSR, Vertex, Vertex Pharmaceuticals, Pharmaceutical industry

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced important advancements across its suzetrigine pain program, which has the potential to be the first new class of medicine for acute and neuropathic pain in more than two decades.

Key Points: 
  • Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced important advancements across its suzetrigine pain program, which has the potential to be the first new class of medicine for acute and neuropathic pain in more than two decades.
  • Following the positive Phase 3 results in acute pain announced in January 2024, the Food and Drug Administration (FDA) has granted a rolling New Drug Application (NDA) submission for suzetrigine in moderate-to-severe acute pain.
  • Suzetrigine was previously granted FDA Fast Track and Breakthrough Therapy designations in moderate-to-severe acute pain.
  • The company intends to advance its next generation NaV1.8 pain signal inhibitor VX-993 oral formulation into Phase 2 acute pain and peripheral neuropathic pain studies later this year.

Vertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older

Retrieved on: 
Friday, April 26, 2024
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, VRTX, National Health Service, European Commission, Cystic fibrosis, CFTR, Life, European, Disease, Patient, Civil service commission, MHRA, Medication, Vertex Pharmaceuticals, Pharmaceutical industry

“Today’s approval is an important milestone for the cystic fibrosis community.

Key Points: 
  • “Today’s approval is an important milestone for the cystic fibrosis community.
  • As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor) shortly following regulatory approval by the European Commission.
  • Vertex will continue to work with reimbursement authorities across the European Union to ensure access for all other eligible patients.
  • In the U.K., following MHRA approval at the end of 2023, and as a result of the existing reimbursement agreement between Vertex and the National Health Service, eligible infants ages 1 month and older in the U.K. have access to this expanded indication for KALYDECO® (ivacaftor).

Vertex Enters Into Agreement to Acquire Alpine Immune Sciences

Retrieved on: 
Wednesday, April 10, 2024
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Slate, Glomerulonephritis, FASN, Lazard, Lupus nephritis, Kidney, Immunotherapy, BAFF, Centerview Partners, Immunoglobulin A, Autoimmune disease, Hart–Scott–Rodino Antitrust Improvements Act, Patient, Multimedia, Vertex Pharmaceuticals, Pharmaceutical industry

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Alpine Immune Sciences, Inc. (Nasdaq: ALPN), a biotechnology company focused on discovering and developing innovative, protein-based immunotherapies, today announced that the companies have entered into a definitive agreement under which Vertex will acquire Alpine for $65 per share or approximately $4.9 billion in cash.

Key Points: 
  • Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Alpine Immune Sciences, Inc. (Nasdaq: ALPN), a biotechnology company focused on discovering and developing innovative, protein-based immunotherapies, today announced that the companies have entered into a definitive agreement under which Vertex will acquire Alpine for $65 per share or approximately $4.9 billion in cash.
  • The transaction was unanimously approved by both the Vertex and Alpine Boards of Directors and is anticipated to close later this quarter.
  • A subsidiary of Vertex will commence a cash tender offer to purchase all outstanding shares of Alpine common stock.
  • For Alpine, Centerview Partners is acting as exclusive financial advisor and Fenwick & West LLP as legal counsel.

Vertex Enters Into Agreement to Acquire Alpine Immune Sciences

Retrieved on: 
Wednesday, April 10, 2024
Research, Infectious Diseases, Hospitals, Clinical Trials, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Slate, Glomerulonephritis, FASN, Lazard, Lupus nephritis, Kidney, Immunotherapy, BAFF, Centerview Partners, Immunoglobulin A, Autoimmune disease, Hart–Scott–Rodino Antitrust Improvements Act, Patient, Vertex Pharmaceuticals, Pharmaceutical industry

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Alpine Immune Sciences, Inc. (Nasdaq: ALPN), a biotechnology company focused on discovering and developing innovative, protein-based immunotherapies, today announced that the companies have entered into a definitive agreement under which Vertex will acquire Alpine for $65 per share or approximately $4.9 billion in cash.

Key Points: 
  • Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Alpine Immune Sciences, Inc. (Nasdaq: ALPN), a biotechnology company focused on discovering and developing innovative, protein-based immunotherapies, today announced that the companies have entered into a definitive agreement under which Vertex will acquire Alpine for $65 per share or approximately $4.9 billion in cash.
  • The transaction was unanimously approved by both the Vertex and Alpine Boards of Directors and is anticipated to close later this quarter.
  • A subsidiary of Vertex will commence a cash tender offer to purchase all outstanding shares of Alpine common stock.
  • For Alpine, Centerview Partners is acting as exclusive financial advisor and Fenwick & West LLP as legal counsel.

VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES

Retrieved on: 
Tuesday, April 23, 2024
Doctor of Philosophy, VRTX, Vertex Pharmaceuticals, Cell, Patient, Biology, Therapy, Tree, Pharmaceutical industry

TreeFrog and Vertex will collaborate to scale-up TreeFrog's process to produce and amplify cells for Vertex's T1D therapies.

Key Points: 
  • TreeFrog and Vertex will collaborate to scale-up TreeFrog's process to produce and amplify cells for Vertex's T1D therapies.
  • TreeFrog's proprietary technology platform, C-Stem™, is designed to mimic the natural microenvironment, allowing cells to grow exponentially in 3D.
  • The technology will enhance Vertex's ability to generate large amounts of fully differentiated cells for its portfolio of T1D cell therapies.
  • "This collaboration with Vertex advances our business strategy of helping bring best-in-class cell therapies to millions of people — both through our own therapeutic programs, and with best-in-class partners like Vertex.

VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES

Retrieved on: 
Tuesday, April 23, 2024
Doctor of Philosophy, VRTX, Vertex Pharmaceuticals, Cell, Patient, Biology, Therapy, Tree, Pharmaceutical industry

TreeFrog and Vertex will collaborate to scale-up TreeFrog's process to produce and amplify cells for Vertex's T1D therapies.

Key Points: 
  • TreeFrog and Vertex will collaborate to scale-up TreeFrog's process to produce and amplify cells for Vertex's T1D therapies.
  • TreeFrog's proprietary technology platform, C-Stem™, is designed to mimic the natural microenvironment, allowing cells to grow exponentially in 3D.
  • The technology will enhance Vertex's ability to generate large amounts of fully differentiated cells for its portfolio of T1D cell therapies.
  • "This collaboration with Vertex advances our business strategy of helping bring best-in-class cell therapies to millions of people — both through our own therapeutic programs, and with best-in-class partners like Vertex.

Vertex to Announce First Quarter 2024 Financial Results on May 6

Retrieved on: 
Tuesday, April 9, 2024
Health, Genetics, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, International, Webcast, Vertex Pharmaceuticals, Vertex, VRTX

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2024 financial results on Monday, May 6, 2024 after the financial markets close.

Key Points: 
  • Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2024 financial results on Monday, May 6, 2024 after the financial markets close.
  • The company will host a conference call and webcast at 4:30 p.m.
  • To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the “Vertex Pharmaceuticals First Quarter 2024 Earnings Call.”
    The conference call will be webcast live and a link to the webcast can be accessed through Vertex's website at www.vrtx.com in the "Investors" section.
  • To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast.